BIOCORP
14.1.2020 18:02:11 CET | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME) , a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, and SANOFI announce today, the signature of a new contract concerning BIOCORP’s smart sensor Mallya.
Negotiations started in July 2019 have led the BIOCORP and SANOFI teams to strengthen their collaboration, developing real synergies around the Mallya system. A new project aiming at closely associating Mallya with SoloStar insulin pens is thus initiated today.
BIOCORP, which has already received €6 million in upfront payments from SANOFI in 2019, is today receiving a new €1 million upfront payment with an additional €12 million milestone payments spread over the period of the collaboration. Additional revenues will be generated from the production of Mallya devices by BIOCORP on behalf of SANOFI.
Eric Dessertenne, Chief Executive Officer of BIOCORP, commented: " After several months of development work to meet the specific needs of our partner SANOFI, we are pleased with the renewed confidence of our partner who is committed to working alongside us for the design, development and distribution of a brand new device in the Mallya range. Our technology, combined with SANOFI's commercial strength, will make it possible to offer to a very large number of patients with diabetes the most efficient and precise solution for monitoring and follow-up of their pathology on the market. Together, we are convinced that improving compliance remains the last hurdle to enable patients to live in the best possible conditions with this chronic disease. “
The smart sensor will record the dosage when a person uses a SoloStar pen to administer insulin. This information can be combined with blood glucose levels recorded by Sanofi’s digital monitoring platform, which currently includes the MyStar DoseCoach® blood glucose meter and the My Dose Coach™ smartphone app. As a result, users will be able to track more easily how their insulin intake, lifestyle, diet and exercise, contribute to changes in their blood sugar levels. The My Dose Coach platform can also suggest adjustments to insulin dose, as part of a titration algorithm recommended by their physician.
“This partnership will drive meaningful changes by delivering a connected device experience for potentially millions of people living with diabetes who use insulin ,” said Chris Boulton, Head of Integrated Care, Primary Care, Sanofi. “In addition to complementing our portfolio, it helps to build a connected ecosystem that provides people with diabetes, and their physicians, with a long-term overview of their disease management, creating opportunities for improved patient self-care between visits .”
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
.
Follow us on Twitter @BIOCORPSystems
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005458/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DATA and Ericsson Team Up to Scale Private 5G and Physical AI for Enterprises26.2.2026 14:00:00 CET | Press release
Private 5G delivered as a fully managed global service with consistent security and operations worldwide Edge AI and physical AI embedded directly into enterprise connectivity for real-time, autonomous decision-making Together, the companies help enterprises move from pilots to globally scalable, production-ready solutions NTT DATA, a global leader in AI, digital business and technology services, and Ericsson (NASDAQ: ERIC) today announced a multi-year strategic partnership to accelerate enterprise adoption of private 5G and unlock advanced edge AI and physical AI use cases. As organizations look to embed intelligence at the edge across global operations, the partnership will enable AI-driven, outcome-focused transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226356511/en/ NTT DATA x Ericsson By combining Ericsson’s Private 5G and Edge platforms with NTT DATA’s full-stack enterprise network services, wireless
Telekom Srbija Group Secures Landmark International Credit Ratings from Fitch and Moody’s, Marking Historic First for Western Balkans26.2.2026 13:22:00 CET | Press release
First Western Balkans–headquartered company to secure dual global credit ratings, shining a spotlight on the region’s rising growth and international relevance Telekom Srbija Group today announced that it has received international credit ratings from Fitch Ratings and Moody’s Investors Service, marking a historic milestone as the first company headquartered in the Western Balkans to achieve this distinction. Fitch Ratings has affirmed Telekom Srbija’s long-term issuer rating in connection with its debut issuance of bonds on the international financial market, recognizing the Group’s strong market position, resilient cash flow profile and disciplined financial strategy. Moody’s Investors Service has assigned a B1 rating to the company’s bond issuance, underscoring Telekom Srbija’s established operating performance and strategic importance within the regional telecommunications sector. As the first Western Balkans–headquartered company to issue bonds on the international financial marke
PNCC Selects LotusFlare to Power Digital BSS and Commerce Platform for New 4G/5G Standalone Network26.2.2026 13:04:00 CET | Press release
LotusFlare, a provider of a cloud-native, AI-driven digital commerce and monetization platform for communications service providers (CSPs), today announced that Palau National Communications Corporation (PNCC) has selected it to provide a comprehensive commerce and monetization platform, including a full-stack digital business support system (dBSS) as part of PNCC’s broader 4G/5G Standalone (SA) network modernization programme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226869218/en/ Palau National Communications Corporation (PNCC) The LotusFlare solution will support PNCC subscribers across mobile, fixed broadband, and digital TV services, while enabling unique multi-tenant capabilities aligned with PNCC’s long-term digital and regional strategy. PNCC has embarked on a comprehensive technology modernization program focused on increasing speed-to-market, enhancing customer experience, and long-term operational efficie
GoldState Music and Bridgepoint Announce Strategic Partnership Targeting Growth Investments26.2.2026 13:00:00 CET | Press release
Capital will support GoldState Music’s Growth Strategy which will invest in scalable, profitable music-oriented businesses across the music value chainBridgepoint commits a significant investment as lead investor in GoldState’s Growth Strategy Bridgepoint, one of the world’s leading mid-market investors, today announced that it has entered into a strategic partnership with GoldState Music, a premier music investment platform, committing a significant investment as lead investor in GoldState’s Growth Strategy. The capital will support a dedicated investment programme focused on building and scaling high-quality music-oriented businesses globally. GoldState Music is a private investment firm founded in 2022 by industry veteran Charles Goldstuck, who played an integral role in the development of many music enterprises as well as in the careers of numerous major artists and songwriters. The company’s Growth Strategy is focused on investing in and scaling growing businesses operating in the
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics26.2.2026 13:00:00 CET | Press release
Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market. Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small cell lung cancer (NSCLC): CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor. John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: "We anticipate this acquisition will significantly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom